Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Jul 2026

All-Cause and Disease-Specific Mortality Among U.S. Adults Living With Co-Existing Cancer and Atherosclerotic Cardiovascular Disease

Background Despite increasing evidence on the bi-directional association between cancer and atherosclerotic cardiovascular disease (ASCVD), less is known about differences in mortality among individuals with co-existing diseases. Objective We examined all-cause and disease-specific mortality among U.S. adults living with cancer, ASCVD, and co-existing cancer and ASCVD. Methods Among adults aged ≥18 years in the National Health Interview Survey (2005-2018) linked to the National Death Index (through December 31, 2019), we estimated multivariable-adjusted HRs (aHRs) and 95% CIs using Cox proportional hazards models. Mortality outcomes were compared across individuals with cancer alone, ASCVD alone, and co-existing conditions, relative to those with neither condition. Results Among 388,632 individuals, 1.3% had co-existing cancer and ASCVD, representing approximately 3.0 million U.S. adults annually. Over a mean follow-up of 7.2 years, co-existing disease was associated with the highest all-cause mortality (aHR, 2.45 [95% CI: 2.23-2.70]), exceeding ASCVD alone (aHR, 1.93 [1.82-2.04]) and cancer alone (aHR, 1.90 [1.77-2.04]). Co-existing disease was associated with elevated risks of both cancer mortality (aHR, 4.18 [3.48-5.03]) and cardiovascular mortality (aHR, 2.73 [2.30-3.24]). Among those living with co-existing diseases, older age (≥75 years) (aHR, 6.02 [1.97-18.37]), diabetes (aHR, 1.23 [1.03-1.46]), and current/former smoking status (aHR, 1.26 [1.07-1.49]) were associated with increased hazards of all-cause mortality. Conclusions Among community-dwelling U.S. adults living with cancer and/or ASCVD, co-existing disease was associated with substantially higher mortality. These findings highlight the elevated burden of mortality among individuals with co-existing cancer and ASCVD and underscore the importance of integrated cardio-oncology care.

Reed Mszar, Leah M. Ferrucci, D. Satti et al. · 0 citations
Open access Aug 2026

Lipid Profiles and Lipid-Lowering Therapy at the Time of Acute Myocardial Infarction

Background Low-density lipoprotein cholesterol (LDL-C) lowering with lipid-lowering therapy (LLT) is foundational for atherosclerotic cardiovascular disease (ASCVD) prevention. Objectives The purpose of this study was to evaluate LDL-C levels and LLT at the time of acute myocardial infarction (AMI). Methods We retrospectively assessed LDL-C levels and LLT use at presentation and discharge among patients hospitalized with AMI from March 2018 to August 2022. Results Among AMI patients with no prior ASCVD diagnosis (n = 1,159), 94.7% had LDL-C ≥55 mg/dL, 86.7% had LDL-C ≥70 mg/dL, and 33.6% were on outpatient statin therapy prior to admission. Among those not taking LLT and aged 18 to 79 years with available risk data, 89.0% met statin eligibility in the 2026 U.S. dyslpidemia guideline. Among AMI patients with prior ASCVD (n = 689), 81.0% had LDL-C ≥55 mg/dL, 64.7% had LDL-C ≥70 mg/dL, 73.7% were previously on statins, and 3.9% were on combination LLT. Although 94.0% of all AMI patients were discharged on statins (81.8% with high intensity), only 5.0% were discharged with combination LLT. Among patients with prior ASCVD and LDL-C ≥55 mg/dL, 24.9% had an increase in statin intensity, 7.2% received combination LLT, and 47.0% received no LLT intensification at discharge. Conclusions In a contemporary AMI cohort, ∼2 in 3 patients presenting with a new ASCVD diagnosis were not previously on a statin, and nearly all had LDL-C ≥55 mg/dL. Among AMI patients with known ASCVD, ∼1 in 4 were not on a statin, and ∼4 in 5 had LDL ≥55 mg/dL. Combination LLT remained low at presentation and discharge despite suboptimal LDL-C, underscoring actionable gaps in ASCVD management.

Mohammed Essa, Qifan Wu, Yuan Lu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.